-
Response to letter Re: Impact of immune-related adverse events on quality of life and physical functioning in older patients with solid tumors treated with immune checkpoint inhibitors
A. Özkan, Karlijn de Joode, Ellen Kapiteijn, Marije Slingerland, Stephanie M. Zunder, Frederiek van den Bos, +11 more
1citations -
primary analysis of the RANDOMIZED eortc-2139/columbus-ad trial: Adjuvant encorafenib and binimetinib versus placebo in high-risk stage II BRAF-V600E/K melanoma2026 European Journal of Cancer article Biochemistry, Genetics and Molecular Biology Melanoma and MAPK Pathways Open access
Alexander C. J. van Akkooi, Michal Kiciński, Anne-Sophie Govaerts, Axel Hauschild, Piotr Lukasz Rutkowski, Petr Arenberger, +32 more
1citations -
Corrigendum to “Conceptual framework for precision cancer medicine in Germany: Consensus statement of the Deutsche Krebshilfe working group ‘Molecular Diagnostics and Therapy’” [European Journal of Cancer 135 (2020) 1-7]2021 European Journal of Cancer erratum Biochemistry, Genetics and Molecular Biology Cancer Genomics and Diagnostics
Christoph Benedikt Westphalen, Carsten Bokemeyer, Reinhard Büttner, Stefan Fröhling, Verena I. Gaidzik, Hanno Glimm, +57 more
0citations -
Treatment considerations in patients with metastatic pancreatic cancer who did not receive systemic therapy: A population-based study2026 European Journal of Cancer article Medicine Pancreatic and Hepatic Oncology Research Open access
Thijmen H.T. Broekman, Tara M. Mackay, Judith de Vos‐Geelen, Geert A. Cirkel, Merlijn U.J.E. Graus, Jan‐Willem B. de Groot, +9 more
0citations -
Risk of subsequent in situ and invasive lesions after a primary diagnosis of ductal carcinoma in situ with follow-up time up to 28 years2020 European Journal of Cancer article Biochemistry, Genetics and Molecular Biology Breast Cancer Treatment Studies
Maartje van Seijen, Esther H. Lips, Liping Fu, Frederieke H van Duijnhoven, A.M. Thompson, P.H.M. Elkhuizen, +3 more
0citations -
Arcagen: Molecular profiling of rare cancer patients – analysis of the pilot study (87 patients)2020 European Journal of Cancer article Biochemistry, Genetics and Molecular Biology Cancer Genomics and Diagnostics Open access
Marie Morfouace, Isabel Ray-Coquard, Nicolas M Girard, Aleksandra Stevovic, Isabelle Treilleux, Pierre Méeus, +12 more
0citations -
International Cutaneous Lymphomas Pandemic Section (ICLYPS) analysis of CTCL outcomes during COVID-192021 European Journal of Cancer article Medicine Cutaneous lymphoproliferative disorders research Open access
Larisa J. Geskin, Tiffany J. Garcia-Saleem, Oleg E. Akilov, Paula Andrea ENZ, Emmanuella Guenova, Pablo Luis Ortiz-Romero, +7 more
0citations -
Response to letter entitled re: UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients2022 European Journal of Cancer article Pharmacology, Toxicology and Pharmaceutics Pharmacogenetics and Drug Metabolism Open access
Emma C. Hulshof, Mirjam de With, Geert‐Jan Creemers, Henk‐Jan Guchelaar, Ron H.J. Mathijssen, Hans A. J. Gelderblom, +1 more
0citations -
Early detection of breast cancer in high-risk women based on longitudinal changes in serum-based proteins: the TESTBREAST study2022 European Journal of Cancer article Chemistry Advanced Proteomics Techniques and Applications Open access
Sophie C. Hagenaars, B. Ravesteijn, L. Dekker, L. Verhoeff, J. Aalberts, Elma Meershoek‐Klein Kranenbarg, +12 more
0citations -
Corrigendum to “Preclinical evaluation of drug combinations identifies co-inhibition of Bcl-2/XL/W and MDM2 as a potential therapy in uveal melanoma” [Eur J Cancer 126 (2020) 93–103]
Didier Decaudin, Estelle Frisch Dit Leitz, Fariba Némati, Malcy Tarin, Adnan Naguez, Mohamed Zerara, +7 more
0citations -
Effect of breast cancer molecular subtype on axillary treatment strategies based on baseline 18F-FDG PET/CT findings2024 European Journal of Cancer article Biochemistry, Genetics and Molecular Biology Breast Cancer Treatment Studies Open access
C. de Mooij, Janine M. Simons, Cristina Mitea, PJ van Diest, Patricia Joan Nelemans, C. Van der Pol, +4 more
0citations